Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx- Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC) stages and T categories, identifying patients whose mortality risk is substantially higher or lower than staging alone would predict FRIENDSWOOD, Texas, March 27, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patie ...

Abbott Laboratories (NYSE:ABT) is one of the Best Conservative Stocks to Buy Right Now. On March 23, the company announced that it had completed the acquisition of Exact Sciences. As a result of this, Abbott Laboratories (NYSE:ABT) is now a leader in fast-growing cancer screening as well as the diagnostics segment. Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences This acquisition places Abbott Laboratories (NYSE:ABT) well to advance diagnostics, which are more preventative, ...

Aklog described the VA contract as a key milestone, stating Lucid was awarded a contract for EsoGuard under the VA Federal Supply Schedule (FSS) , which centralizes ordering and sets pricing aligned with the company’s established Medicare rate of $1,938 . He said securing the contract without discounting relative to Medicare was an important validation of the company’s clinical evidence.In the Q&A, management said the sequential increase in volume was not attributable to VA testing, which is still in the ea ...

Lucid Diagnostics (NasdaqCM:LUCD) Q4 2025 Earnings call March 26, 2026 08:30 AM ET Company ParticipantsDennis McGrath - CFOJeremy Pearlman - Senior Research AssociateLishan Aklog - Chairman and CEOMatt Riley - VP of Investor RelationsConference Call ParticipantsKyle Mikson - Managing Director and Senior Research AnalystMark Massaro - Managing Director and Life Science and Diagnostic Tools AnalystMike Matson - Senior AnalystOperatorGood morning, and welcome to the Lucid Diagnostics fourth quarter 2025 busine ...

Anticipated Earnings Release: Co-Diagnostics, Inc. (NASDAQ:CODX) is set to announce its Q4 and full-year 2025 financial results on March 31, 2026, with an expected EPS of -$3.60.Financial Metrics Overview: CODX showcases a mixed financial outlook with a price-to-sales ratio of 4.44 and an enterprise value to operating cash flow ratio of 0.25, indicating positive market perception and efficient cash flow conversion, respectively.Challenges Ahead: Despite strong liquidity and a conservative capital structure, ...

Co-Diagnostics Begins Shipments To Support India TB StudiesThese materials are necessary to begin clinical performance studies of the TB test on the PCR platform, as the company completes final steps toward initiating those studies in the near term.Last week, Co-Diagnostics signed an agreement for CoSara Diagnostics Pvt. Ltd, to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka.WHO Guidance Aligns With Company's TB Testing ApproachThe co ...

Personalis, Inc. (NASDAQ:PSNL) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its price target from Morgan Stanley lowered from $11 to $10. The firm’s analyst maintained an Equal Weight rating on the stock after updating its estimates to reflect an increased 2026 net loss guidance and higher projected long-term operating expenses. In another development, ...

CareDx, Inc. (NASDAQ:CDNA) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. CareDx (CDNA) Launches AI Platform VANTx On March 5, 2026, CareDx, Inc. (NASDAQ:CDNA) launched VANTx, an AI-powered, cloud-native platform designed to transform complex transplant data into actionable clinical insights. The platform, introduced at the 2026 Precision Medicine World Conference, analyzes patient cohorts, treatment trends, and real-world evidence with the help of Llama 3 and advance ...

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q4 2025 Earnings Webinar ...

CoSara is the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited.Co-Diagnostics, most recently, regained NASDAQ listing compliance.Territory Expansion Unlocks $13 Billion Market OpportunityThe expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13 billion based on internal analyses and third-party market data.It also supports CoSara's plans to commercialize the CoSara PCR Pro point-of-care instrume ...